OSCRHealthcare · Healthcare PlansThe 11 Wall Street analysts covering Oscar Health, Inc. hold a median 12-month price target of $34 — -3.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 90 of 100 as at 4 Nov 2026 — among the strongest tenth. The factors read stronger than the Street's target implies. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Oscar Health, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (96): Sales and profits are climbing, and climbing faster than before.
Issuance (23): The company has been issuing shares or taking on financing, diluting existing holders.
Size (15): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on OSCR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits −3.4% from it.
Of the 20 most recent actions, 9 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 12 Oct 2026 | UBS | Maintains | Neutral | $26 → $36 |
| 18 Sept 2026 | Raymond James | Maintains | Outperform | $34 → $42 |
| 18 Sept 2026 | Raymond James | Maintains | Outperform | — |
| 17 Sept 2026 | B of A Securities | Maintains | Underperform | — |
| 17 Sept 2026 | B of A Securities | Maintains | Underperform | $28 → $30 |
| 17 Sept 2026 | Baird | Maintains | Neutral | — |
| 17 Sept 2026 | Baird | Maintains | Neutral | $27 → $33 |
| 17 Sept 2026 | Barclays | Maintains | Overweight | $39 → $49 |
| 17 Sept 2026 | Barclays | Maintains | Overweight | — |
| 17 Sept 2026 | Stephens & Co. | Reiterates | Equal-Weight | — |
| 17 Sept 2026 | Stephens & Co. | Reiterates | Equal-Weight | $34 |
| 13 Aug 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 13 Aug 2026 | Wells Fargo | Maintains | Equal-Weight | $20 → $27 |
| 7 Aug 2026 | Barclays | Maintains | Overweight | — |
| 7 Aug 2026 | Barclays | Maintains | Overweight | $35 → $39 |
| 7 Aug 2026 | UBS | Maintains | Neutral | $20 → $26 |
| 7 Aug 2026 | UBS | Maintains | Neutral | — |
| 10 June 2026 | Barclays | Upgrade | Overweight | $30 → $35 |
| 10 June 2026 | Barclays | Upgrade | Overweight | — |
| 26 May 2026 | Barclays | Maintains | Equal-Weight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
OSCR appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Oscar Health, Inc. returned +105.1% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 30% of US stocks
Cheaper than 77% of US stocks
Cheaper than 19% of US stocks
Cheaper than 56% of US stocks
Higher than 90% of US stocks
Higher than 80% of US stocks
Higher than 61% of US stocks
Higher than 56% of US stocks
Higher than 89% of US stocks
Higher than 73% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Oscar Health, Inc. has a market value of $10.0B and an enterprise value of $1.9B.
Revenue in the twelve months to 30 June 2026: $15.3B. The latest quarter grew 70.4% year on year.
Net income over the same four quarters: $550.9M, a 3.6% net margin.
Diluted earnings per share, trailing twelve months: $1.40.
Free cash flow in the twelve months to 30 June 2026: $4.4B.
Trailing P/E: 25.1×; forward P/E: 14.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Oscar Health, Inc. employs 2,305 people — $6.6M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Oscar Health, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Oscar Health announced its financial results for the third quarter ended September 30, 2026, and raised its full-year 2026 outlook.
Why it matters — The quarterly results and updated outlook provide OSCR watchers with the company’s latest financial update and expectations for the year.
Healthcare stocks tied to state Medicaid programs, Affordable Care Act markets and hospital groups jumped following midterm results, according to Barron's.
Why it matters — Oscar Health operates in the health insurance sector, so the reported rise in stocks linked to Affordable Care Act markets is relevant context for OSCR watchers.
MarketWatch reports that the Democratic victory in the midterm elections could benefit the nation’s largest hospitals, while healthcare companies face differing prospects for scrutiny.
Why it matters — The excerpt describes a potential shift in the healthcare sector but does not state a direct effect on Oscar Health.
Zacks Investment Research reported that OSCR was included on its Zacks Rank #1 (Strong Buy) growth stocks list for November 4, 2026, alongside MDB and ATI.
Why it matters — The item identifies OSCR as part of Zacks’ top-ranked growth stocks list on that date.
Oscar Health’s Q3 revenue is projected to rise 58.1% to $4.7 billion, while the company is still expected to report an 11-cent loss. The item asks whether the company can deliver an earnings surprise this season.
Why it matters — OSCR watchers may track the revenue outlook alongside the projected quarterly loss as earnings approach.
The 11 Wall Street analysts covering Oscar Health, Inc. have a median 12-month price target of $34, with estimates ranging from $27 to $49. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 11 analysts covering Oscar Health, Inc., 3 rate it a Buy, 7 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Oscar Health, Inc. 90 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, Oscar Health, Inc. ranks 90 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (96 of 100).
No one can know that. What the data says: the median 12-month target from 11 analysts implies -3.4% from the last close, and Ticker Nerd's factor model ranks Oscar Health, Inc. 90 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Oscar Health, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OSCR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $27 to $49 over the next 12 months.
Oscar Health, Inc. returned +105.1% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Oscar Health, Inc. Class A Common Stock represents ownership in Oscar Health, a healthcare technology company focused on health insurance products and digital member services in the United States.
The most recent item we track (Business Wire, 5 Nov 2026): "Oscar Health Announces Financial Results for Third Quarter 2026 and Raises Full Year 2026 Outlook". Oscar Health announced its financial results for the third quarter ended September 30, 2026, and raised its full-year 2026 outlook.
Oscar Health, Inc. Class A Common Stock represents ownership in Oscar Health, a healthcare technology company focused on health insurance products and digital member services in the United States. Oscar Health combines insurance coverage with a technology platform designed to help members access care, manage plans, and navigate the healthcare system. Its current offerings include individual and family health plans, small group coverage, and Medicare Advantage plans, along with technology solutions for providers and payors. The company operates in the managed health care and health services space, where it serves consumers and business customers through a data-driven, consumer-oriented model. Headquartered in New York, Oscar Health is positioned as a modern health insurer that integrates software, service, and clinical support across its insurance operations.
CEO Mr. Mark Thomas Bertolini · 2,305 employees · United States · https://www.hioscar.com
